Clinical Trial Update: Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Dimolegin (DD217) for prevention of thrombotic complications in hospitalized COVID-19 patients has completed enrollment/terminated st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Dimolegin (dimolegin)

Snippet

Sponsor: PharmaDiall Ltd. | Conditions: COVID-19, Venous Thromboembolism | Phase 3 | Status: COMPLETED